当前位置:首页 - 行情中心 - 东星医疗(301290) - 财务分析 - 利润表

东星医疗

(301290)

  

流通市值:17.23亿  总市值:25.32亿
流通股本:6816.34万   总股本:1.00亿

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入283,737,516.84183,292,306.6178,186,465.07435,463,080.43
  营业收入283,737,516.84183,292,306.6178,186,465.07435,463,080.43
二、营业总成本245,520,282.82163,130,797.3872,372,834.27358,927,111.5
  营业成本147,468,580.1597,573,435.1443,469,650.62220,492,163.52
  税金及附加4,043,497.652,498,396.891,060,168.715,179,633.04
  销售费用33,791,434.1122,308,254.638,190,354.2647,576,239.82
  管理费用46,609,223.7632,249,472.0815,240,570.0665,369,542.32
  研发费用13,107,931.238,419,735.464,169,622.1122,433,892.09
  财务费用499,615.9281,503.18242,468.51-2,124,359.29
  其中:利息费用862,315.13518,203.73176,906.96338,527.01
  其中:利息收入809,921.85777,545.4115,402.242,699,802.9
三、其他经营收益
  加:公允价值变动收益807,275.542,662,563.62107,681.68-7,000,940.2
  加:投资收益18,893,562.4711,144,971.246,486,358.2836,695,547.36
  资产处置收益-18,726.95-12,070.87-356.13-83,679.38
  资产减值损失(新)-103,633,640.8819,648.12-29,647-480,308.03
  信用减值损失(新)1,278,685.661,293,770.041,018,541.47-246,809.35
  其他收益1,921,865.181,208,559.61904,710.0910,222,971.26
四、营业利润-42,533,744.9636,478,950.9914,300,919.19115,642,750.59
  加:营业外收入92,271.7476,262.5518,845.23177,247.22
  减:营业外支出649,699.81646,794.0517,632.78756,936.75
五、利润总额-43,091,173.0335,908,419.4914,302,131.64115,063,061.06
  减:所得税费用10,430,618.766,254,071.552,628,534.5418,171,882.27
六、净利润-53,521,791.7929,654,347.9411,673,597.196,891,178.79
(一)按经营持续性分类
  持续经营净利润-53,521,791.7929,654,347.9411,673,597.196,891,178.79
(二)按所有权归属分类
  归属于母公司股东的净利润-53,201,637.4930,292,870.9712,063,975.2297,424,753.19
  少数股东损益-320,154.3-638,523.03-390,378.12-533,574.4
  扣除非经常损益后的净利润-69,618,643.6819,036,505.316,267,512.0366,459,147.18
七、每股收益
  (一)基本每股收益-0.530.30.120.98
  (二)稀释每股收益-0.530.30.120.98
九、综合收益总额-53,521,791.7929,654,347.9411,673,597.196,891,178.79
  归属于母公司股东的综合收益总额-53,201,637.4930,292,870.9712,063,975.2297,424,753.19
  归属于少数股东的综合收益总额-320,154.3-638,523.03-390,378.12-533,574.4
公告日期2025-10-292025-08-282025-04-252025-04-15
审计意见(境内)标准无保留意见
TOP↑